[Drug-Resistant Mechanism of Multiple Myeloma and Its Therapy Combined with HDACi -Review]
- PMID: 28446321
- DOI: 10.7534/j.issn.1009-2137.2017.02.055
[Drug-Resistant Mechanism of Multiple Myeloma and Its Therapy Combined with HDACi -Review]
Abstract
Drug resistance of multiple myeloma(MM) has become more and more common, and greatly decreased the survival rate of these patients. The occurence of drug-resistance involves in many factors such as bone marrow microenveronment, tumor cell self-metabolism, cytokines, specific targets and so on. In this review, the potential mechanisms of resistance to glucocorticoid/proteasome inhibitor/immunomodulatory druges are briefly expounded in the aspect of tumor cell self-metabolism, including the changes of heat slock protein expression, mRNA expression, related cytokine levels and down-regulation of thalidomid-effecting site CRBN expression. In this review, the researches on the effect of histone deacetylase inhibitors(HDACi) combined with glucocorticoid, proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies on multiple myeloma, specially, drug-resistant multiple myeloma are also summarized.
Similar articles
-
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.Br J Haematol. 2015 Dec;171(5):798-812. doi: 10.1111/bjh.13780. Epub 2015 Oct 12. Br J Haematol. 2015. PMID: 26456076 Free PMC article.
-
Resistance to proteasome inhibitors and other targeted therapies in myeloma.Br J Haematol. 2018 Jul;182(1):11-28. doi: 10.1111/bjh.15210. Epub 2018 Apr 20. Br J Haematol. 2018. PMID: 29676460 Review.
-
Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton.Cell Death Dis. 2014 Mar 20;5(3):e1134. doi: 10.1038/cddis.2014.98. Cell Death Dis. 2014. PMID: 24651437 Free PMC article.
-
The proteasome and proteasome inhibitors in multiple myeloma.Cancer Metastasis Rev. 2017 Dec;36(4):561-584. doi: 10.1007/s10555-017-9707-8. Cancer Metastasis Rev. 2017. PMID: 29196868 Review.
-
Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):752-765. doi: 10.1016/j.clml.2021.06.020. Epub 2021 Jun 26. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34340951 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical